These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 16585050)

  • 1. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.
    Costa J; Borges M; David C; Vaz Carneiro A
    BMJ; 2006 May; 332(7550):1115-24. PubMed ID: 16585050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes.
    Karalis DG
    Clin Cardiol; 2008 Jun; 31(6):241-8. PubMed ID: 17847038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrates for primary prevention of cardiovascular disease events.
    Jakob T; Nordmann AJ; Schandelmaier S; Ferreira-González I; Briel M
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009753. PubMed ID: 27849333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening and management of coronary artery disease in diabetic patients].
    Kraiem S; Abassi C; Annabi N; Smaali I; Issaa I; Wali M; Malou M; Hannachi S; Longo S; Battikh K; Slimane ML
    Tunis Med; 2006 Oct; 84(10):670-6. PubMed ID: 17193866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
    Keating GM
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Do we reach target lipid levels in diabetic and non-diabetic patients with previous myocardial infarction?].
    Aleksić E; Stamenković R; Lapcević M; Deljanin-Ilić M; Djordjević D; Tasić I
    Srp Arh Celok Lek; 2011; 139(1-2):30-6. PubMed ID: 21568080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotics for secondary prevention of coronary heart disease.
    Sethi NJ; Safi S; Korang SK; Hróbjartsson A; Skoog M; Gluud C; Jakobsen JC
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD003610. PubMed ID: 33704780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes.
    Gami AS; Montori VM; Erwin PJ; Khan MA; Smith SA;
    BMJ; 2003 Mar; 326(7388):528-9. PubMed ID: 12623912
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials.
    Pignone M; Phillips C; Mulrow C
    BMJ; 2000 Oct; 321(7267):983-6. PubMed ID: 11039962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians.
    Vijan S; Hayward RA;
    Ann Intern Med; 2004 Apr; 140(8):650-8. PubMed ID: 15096337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis.
    de Vries FM; Denig P; Pouwels KB; Postma MJ; Hak E
    Drugs; 2012 Dec; 72(18):2365-73. PubMed ID: 23186103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins for diabetic cardiovascular complications.
    Ludwig S; Shen GX
    Curr Vasc Pharmacol; 2006 Jul; 4(3):245-51. PubMed ID: 16842142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus.
    García Díaz E; Ramírez Medina D; Morera Porras ÓM; Cabrera Mateos JL
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):223-231. PubMed ID: 30541682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.